Abstract Mitochondrial respiratory chain diseases are a heterogeneous group of pathologies caused by genetic alterations affecting mitochondrial energy production. Theoretically, this deficiency may lead to any symptoms, in any organ or tissue, at any age even before birth. The aim of our study was to identify the frequency and characterize antenatal manifestations identifying possible associations between mitochondrial disease and more specific and earlier manifestation. We retrospectively review the files of 44 paediatric subjects with genetic and biochemical alterations of respiratory chain identified in the first decade of life and compare data with a control group (n088). Our results show that maternal age was similar in both groups. The female gender was predominant in patients group. Gestational age at delivery was similar in both groups. Concerning birth weight, it was significantly lower (p00.001) in patients (2899.9±538.3 vs. 3246.6±460.2 g). Fifteen pregnancies of the patients group were considered abnormal. Our findings show that intrauterine growth restriction was the most frequent antenatal feature observed. Neonatal morbidity was significantly higher (fivefold) in patients (p<0.001). The clinical findings are independent of the molecular defect type. Our results are preliminary and more studies are needed, in order to learn more about mitochondrial physiology and activity in embryological development for the assessment of mitochondrial disease progress in fetal life. However, the present work is a significant contribution, given the scarcity of information in this field.
Introduction
Mitochondria are crucial organelles within the cell and its main function is to produce and provide energy for cellular metabolism in most organs and tissues, through a process called oxidative phosphorylation (OXPHOS). This process occurs in a multienzymatic system located in the mitochondrial inner membrane -the mitochondrial respiratory chain (MRC), which has components encoded by the two genomes, mitochondrial (mtDNA) and nuclear DNA (nDNA). MRC is organized in five polypeptides (I-V) and two intermediate electron carriers -coenzyme Q or ubiquinone and cytochrome C. Apart from complex II, which is exclusively encoded by nDNA, complexes I, III, IVand V are encoded by both nDNA and mtDNA (Van den Heuvel and Smeitink 2001) .
Mitochondrial respiratory chain diseases (MRCD) are a heterogeneous group of pathologies due to genetic mutations affecting mitochondrial energy production. The estimated incidence of these diseases is approximately 1:10,000 births (Van den Heuvel and Smeitink 2001) with minimum incidence in child and adulthood is 1:5000 (Schaefer et al 2004) . Epidemiological studies have shown that average prevalence in children is about 1:20,000, indicating MRCD as the most common group of inherited metabolic disease (Schaefer et al 2004) .
The Portuguese data from "Centro" region, in the period [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] , in a population of a tertiary paediatric hospital, revealed an incidence of 1.5:10,000 and a prevalence of 5.4:100,000 in children, under 10 years (Diogo et al 2009) .
In theory, a defect of OXPHOS can lead to any symptom, in any organ or tissue, at any age or even before birth Suomalainen 2011) , due to the bigenomic origin of the MRC components (Van den Heuvel and Smeitink 2001; Munnich 2000; Alberio et al 2007; Spinazzola and Zeviani 2009) . Although MRC disorders may disclose with possible multiple clinical presentations, it should be suspected when there is an unexplained combination of neuromuscular disease and/or neuromuscular symptoms involving different organs and systems with progressive course . There is limited information on the antenatal manifestations of MRC deficiencies. Some authors consider that around 20 % of the newborns will be small for gestational age, illustrating the importance of this antenatal expression of the disease . A more recent study showed that although a number of metabolic disease undergo a symptom-free period, respiratory chain deficiency may have an early antenatal expression, probably related to the time course and/or tissue specificity of the disease gene expression in the embryofetal period (Von KleistRetzow et al 2003) .
The aim of the present study was to evaluate the frequency and characterize the antenatal manifestations of MRC disorders in a population of children carrying genetic mtDNA alterations and to identify possible associations between MRC disorders and a more specific and earlier manifestation and diagnostic disclosure of these diseases.
Design and methods
The files of a group of 44 subjects in paediatric age, with clinical manifestations of MRCD in the first decade of life, investigated at the Biochemical Genetics Laboratory -Center for Neuroscience and Cell Biology and Faculty of Medicine, University of Coimbra, in a period of 10 years (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) were retrospectively reviewed.
Patients were classified according to adapted Bernier criteria for MRC disorders in children (Bernier et al 2002) . A definite diagnosis was considered if two major or one major plus two minor criteria were fulfilled. Presence of one major plus one minor or three or more minor criteria defined a probable MRC disorder. One major or two minor criteria defined a possible MRC disorder. For these diagnostic groups, the presence of both clinical and laboratorial criteria was obligatory (Diogo et al 2009) . In the presence of a clinical presentation suggestive of MRCD and deletions, the case was classified as a probable MRCD; if a single mtDNA deletion or depletion was found, a definite MRCD was established.
Total DNA was extracted from samples by standard methods (Treco 1999) and quantified by UV spectrophotometry (λ0260 nm).
Determination of mtDNA copy number was performed by real-time PCR as previously described (Venegas et al 2011) . The criterion used to establish mtDNA depletion was the presence of <30 % mtDNA copy number as described by Rahman and Poulton (2009) , compared with age and tissue matched controls.
Automated sequencing analyses were performed, according to the manufacturer's instructions (3130 ABI Prism sequencing system), using BigDye® Terminator Ready Reaction Mix v1.1 (Applied Biosystems), for investigation of 11 mtDNA regions corresponding to nucleotides 1435-1917, 3150-3769, 4074-4703, 4886-5021, 7241-7644, 8222-8461, 8915-9413, 11720-11819, 13515-13727, 14420-14855, 15023-15450 , allowing the screening of 31 confirmed pathogenic mutations, 105 reported mutations and 288 polymorphisms, including four haplogroup markers, according to MITOMAP (www.mitomap.org).
Flanking PCR was performed for investigation of deletions in six mtDNA regions corresponding to nucleotides 3150-14704, 3150-16192, 3150-16406, 7241-14704, 8222-13727 and 8222-16192 , followed by an electrophoresis to check the existence of deletions. The result was considered positive if the deletions were detected in three independent assays. Confirmation and location of deletions was performed by sequencing analysis as described above.
Biochemical analysis of MRC enzymatic complexes was performed in freeze-thawed samples. The storage period was 7 days at −80°C for all samples Lymphocytes were isolated in Ficoll gradient (Rustin et al 1994) , in the same day of blood collection and the pellet ressuspended in PBS. Fibroblasts were freshly obtained by culture from skin biopsy (Gibson et al 1998) . Biopsy tissues were immediately frozen at patient's bedside. Tissue homogenization was performed according to Rustin et al 1994 . Evaluation of MRC complexes I (NADH-coenzyme Q reductase, EC 1.6.5.3), II (succinate dehydrogenase, EC1.6.5.1), II+III (succinate-cytochrome c oxiredutase, EC1.3.99.1), III (ubiquinol cytochrome c reductase, EC1.10.2.2), IV (cytochrome c oxidase, EC1.9.3.1), V (ATP synthase, EC 3.6.1.34) and citrate synthase (CS, EC 4.1.3.7) activities was performed using double wavelength spectrophotometry, according to Grazina (2012) using a spectrophotometer SLM Aminco connected to a register under controlled temperature conditions (all the assays were performed at 37°C). Citrate synthase (CS) was used as a mitochondrial reference enzyme. In brief, for complex I evaluation was obtained by using NADH as electron donor and ubiquinone as acceptor, at 340-380 nm; complex II activity was measured at 600-750 nm by the reduction of 2,6-dichloroindophenol (DCPIP) triggered by succinate; complex II+III was evaluated at 550-540 nm following the reduction of cytochrome c by complex III coupled to succinate oxidation; complex III was monitored at 550-540 nm by reduction of cytochrome c with decylubiquinol as substrate; complex IV activity was measured by following the oxidation of reduced cytochrome c at 550-540 nm using the detergent dodecylmaltoside. Complex V activity was obtained by following ADP phosphorylation; citrate synthase assay followed the reaction of 5,5'-dithiobis 2-nitrobenzoic acid (DTNB), with coenzyme A which is formed by citrate synthase reaction from acetyl CoA and oxaloacetate at 412-600 nm, using detergent TritonX-100 20 %. Protein was determined by the Bradford method and results were expressed in nmol of oxidized substrate/min/mg protein.
The antenatal and neonatal history was obtained from clinical history files of Obstetric Unit of University Hospital of Coimbra and Metabolic Diseases Unit, Centre for Child Development "Luís Borges", Paediatric Hospital of Coimbra.
In order to evaluate the significance of the findings, a control group (n088) was included: two healthy infants matching patients by the month and year of birth, from the database of the delivery room of Obstetric Unit of University Hospital of Coimbra, for each case of a child with MRCD diagnosis.
The following parameters were evaluated in both patients (group A) and controls (group B): maternal age, maternal and/or family history of pathology (including neuromuscular or cardiac), previous obstetrical history in multiparous women (history of preterm labour, intrauterine growth restriction and fetal death), complications during actual pregnancy-namely infections (cytomegalovirus, toxoplasmosis, varicella), intrauterine growth restriction (IUGR)-defined as estimated fetal weight below 10th percentile for gestational age (Hadlock), abnormal ultrasound findings (oligohydramnios-defined as amniotic fluid measurement inferior than 5 cm), hypertension, preterm delivery (PTD)-defined as delivery before 37 weeks of gestation, gestational age at delivery, mode of delivery, complications at delivery, birth weight and Apgar index of the newborn (NB), neonatal morbidity [subdivided in the following categories: respiratory-respiratory distress syndrome (RDS); neurologicalhypotonia/poor spontaneous movements; metabolichypoglycaemia, jaundice, cholestasis and hepatic failure; infectious-sepsis; gastrointestinal-anorexia, vomiting] and neonatal mortality. Pregnancies were considered abnormal when any complication described above was registered.
Statistical analysis was performed using SPSS 13.0® Statistical Software (SPSS Inc, Chicago, IL) to compare the results between cases and controls. For quantitative variables, the existence of a normal distribution was studied by Kolmogorov-Smirnov Test and homogeneity of variances by Levene's Test. When the results followed a normal distribution and homogeneity of variances was found, a tTest for data comparison between the groups was carried out. Whenever the condition of normality underlying quantitative variable under study and/or the condition of homogeneity failed, the nonparametric Wilcoxon-Mann-Whitney Test was used. The qualitative variables were organized in contingency tables and χ2 or Fisher's exact tests were used to perform association analysis. The strength of the association was evaluated by Pearson's contingency measure. A p value <0.05 was considered for defining statistical significance.
Results
A total of 44 patients (group A) and 88 control subjects (group B) were included in this study. The probable pathogenic mtDNA alterations of the patients included: depletion (n011), point mutations (n04), deletions (n026), deletion and point mutations (n01). An isolated nDNA variation was present in one patient and nDNA alteration plus depletion in four patients. Table S1 summarizes all clinical manifestations, diagnostic and the alterations found in genetic and biochemical studies. In Table S2 we present in detail the genes affected by mtDNA deletions.
The results obtained from files analysis for the prenatal and neonatal history are described below with comparison between the two groups.
Maternal age was 28.4±6.5 and 28.3±4.7 years (average± sd), for groups A and B, respectively. Gestational age (GA) at delivery was 38.6±1.7 and 38.5±2.6 weeks, respectively. The ratio of children gender (male:female) was 0.43 vs 1 and birth weight at delivery was 2,899.9±538.3 vs 3,246.6±460.2 g (p00.001).
One third of mothers vs two thirds were nulliparous. In previous obstetrical history PTD was found in 2 vs 3 cases and IUGR in 1 vs. 0.
Concerning family history, neurological diseases were found in 8 vs. 5 cases and other genetic diseases in 2 vs 0 [One case of Cohen syndrome and another of Ornithine transcarbamylase (OTC) deficiency].
Six children with MRCD had consanguineous parents (four in first degree) compared to zero in control group (p00.001).
Fifteen pregnancies of group A were considered abnormal (15/44; 34 %). The anomalies observed were: IUGR (n09), oligohydramnios (n02), PTD (n02), fetal anemia/ anasarca (n01), maternal infection with varicella (n01), poor fetal movements (n01) ( Table S3 ). All these anomalies were diagnosed in the third trimester of pregnancy, except the maternal infection by varicella. No fetal malformations were observed.
Regarding the type of delivery, 8 vs. 16 were born by csection; 5 vs. 8 of those were performed due to fetal distress.
Low Apgar score index, considered as less than three at the first minute and less than 7 at 5 min of life were found in 1 and 2 newborns with MRCD, respectively.
Neonatal morbidity (Table S4 ) is significantly higher (fivefold) in group A (p<0.001).
Neonatal mortality was observed in one patient with MRCD in the first day of life. He was born at 25 weeks of gestation. The cause of death was respiratory insufficiency by pulmonary hypertension.
Given the high number of cases with deletions (n026), data were analyzed excluding deletions (patients n018; controls n088) and the results obtained were similar, showing that the manifestations are independent of the molecular defect type. We found statistical difference when compared with controls in consanguineous parents (p00.001), gestational events with higher prevalence of IUGR (p00.006), birth weight at delivery (p00.001) and neonatal morbidity (p<0.001), particularly neurological (p<0.001) and metabolic (p<0.001).
Discussion
There is limited information on the antenatal manifestations of MRC deficiencies. Yanicostas et al (2011) and DiMauro and Garone (2011) reflected about development aspects of MRC from fetus to infancy and conclude that little is known about mitochondrial function during fetal life in humans. These authors conclude that intuitively, because of fetal development and its high energy demanding process mitochondria will be in full action, as the most active machinery in delivering cellular consumable energy. However, some experiments with mammals, especially in mouse, have shown that mitochondrial activity varies during fetal life from few and short activity at embryonic mitochondria to active metabolic activity in differentiated cells. In the first trimester of pregnancy, the embryo develops in a low oxygen environment with low levels of biosynthesis, whereas in the third trimester, high oxidative metabolism takes place through the mitochondria to sustain the rapid fetal growth.
In conclusion, the mentioned authors' defend that MRC anomalies will only affect fetal life when it relies on newly synthesized mitochondria.
The male/female ratio of 0.43:1 in group A is different from those found in literature. Scaglia et al (2004) and Skladal et al (2003) describe a male/female ratio of 1.5:1 in groups of 113 and 75 paediatric patients, respectively.
There was no evidence for family history of MRCD, but we found a higher incidence of neurologic diseases in family relatives and there was higher prevalence (with statistical significance -p 00.001) of first degree consanguineous parents in MRCD patients.
The findings reveal that 34 % (15 out of 44) of patients had unspecific antenatal manifestations. Intrauterine growth restriction was the most frequent antenatal feature observed. Other isolated antenatal manifestations, such as oligohydramnios and decrease fetal movements were observed, in agreement with findings by Gibson et al (2008) and Von Kleist-Retzow et al (2003) . However, in the present analysis, the type and frequency of anomalies were not similar to what has been described by those authors, especially when concerning antenatal malformations and multiple organ involvement. In fact, we had no evidence of cardiac abnormalities, central nervous system malformations or other complex malformations and with multiple organ involvement like others described. The results obtained are coincident with data reported by that consider that mitochondrial diseases are not commonly regarded as causes of fetal malformation. Yanicostas et al (2011) and DiMauro and Garone (2011) stated that in the third trimester, high oxidative metabolism takes place through mitochondria to sustain the rapid fetal growth. This suggests that in a presence of a MRCD, fetal growth can be compromised in the last trimester. The prevalence of IUGR in group A is relevant and all cases were detected in the last trimester of pregnancy in agreement with the mentioned authors'.
We have found evidence that low birth weight was more frequent (threefold) in children with MRCD when compared with control group (p00.003). These results are similar to those described by Von Kleist-Retzow et al (2003) . Gibson et al (2008) suggest that the high energy demands of labor, delivery and the early neonatal period increases the vulnerability of children with MRCD, because they have an impaired energy production. However, the majority of MRCD patients were born by vaginal delivery with satisfactory Apgar score index, not significantly different from controls. Nevertheless, the nine C-sections performed in patients were by fetal distress although there is an apparent lack of association between MRCD and the type of delivery. However, a higher number of neonates with MRCD had significantly more manifestations when compared to controls (p<0.001). Data in Table S4 shows that the most frequent neonatal manifestations were neurological with hypotonia/poor spontaneous movements (p00.001) and metabolic with recurrent hypoglycaemia (p00.04). These results are coincident with those described in the literature (Munnich 2000; .
Recently, Honzik et al (2012) described the neonatal manifestations of MRCD in a group of 129 neonates and hypotonia was observed in 90 % of cases. Data presented in Table S4 shows that in five out of 15 patients with neonatal clinical presentation (33 %), had hypotonia, which is a lower frequence, but in the present study only 15 of the 44 studied patients had neonatal manifestations.
Maternal age, pregnancy complications as hypertension or fetal deaths, gestational age at delivery and neonatal mortality were found not to be significantly different between the two groups. These results are similar to those described by Von Kleist-Retzow et al (2003) .
Concerning the patients investigated in the present work, the tissue more often analyzed was muscle. The most affected enzymatic complexes were complex I and IV. Deletions were the most frequent mtDNA alteration identified in our sample, but other pathogenic mtDNA alterations were found, as well as nDNA alterations.
Deletions and duplications are part of the second class of mtDNA alterations-the rearrangements. They are usually sporadic, heteroplasmic and unique, and frequently are caused by de novo rearrangements that arose during oogenesis or early development. The estimated incidence of single mtDNA deletion, in general population, is 1 in 83,000 (Chinnery et al 2004) . No correlation has been referred between clinical presentation and the nature or extent of rearrangements. Another important characteristic is that deletions increase in proportion over the course of the disease, suggesting that they have a replicative advantage over normal molecules .
Additionally, mtDNA deletions could be present in close maternal relatives indicating that maternal inheritance may occur. Multiple deletions of mitochondrial DNA (mtDNA) have been associated with a number of autosomal disorders classified as defects of nuclear-mitochondrial intergenomic signaling. The mendelian forms of progressive external ophthalmoplegia (PEO) are clinically and genetically heterogeneous disorders characterized by the accumulation of multiple deletions of mtDNA in postmitotic patient's tissues. Most of the autosomal dominant PEO (adPEO) families carry heterozygous mutations in either one of three genes: ANT1, Twinkle, and POLG1 (Spinazzola and Zeviani 2005) .
Because of these peculiarities of mtDNA deletions and in order to strengthen our results, we made the same statistical analysis excluding the patients carried this mtDNA defect (n0 26). The results are similar. We obtained statistical difference when compared with controls in consanguineous parents (p0 0.001), gestational events with higher prevalence of IUGR (p00.006), birth weight at delivery (p00.001) and neonatal morbidity (p<0.001), particularly neurological (p<0.001) and metabolic (p<0.001). With this results we could think that there are probably some other mutations, that have not been found yet, which are associated with deletion and give them the strength to cause a pathogenic mutation. It is evident that we have identified an elevated number of cases with mtDNA deletions (n026), which is higher than usually described in other studies. In our laboratory, we have a deep screening strategy for mtDNA deletions identification all over the genome and not restricted to the common deletion. Additionally, it has been suggested that MRCD in paediatric age is mainly caused by nuclear DNA mutations (Schon 2000; RubioGozalbo et al 2000) . Since deletions are mainly caused by errors in nuclear genes responsible for mtDNA replication/ maintenance , our results are in agreement with this assumptions.
It is worth mentioning that, in case of m.1555A>G (patient 29), it has been described by Prezant et al (1993) associated with both antibiotic-induced and nonsyndromic deafness; however, an atypical presentation of the same mutation has also been reported in a case of maternally inherited cardiomyopathy without deafness (Santorelli et al 1999) . Also, we had just identified another case (results not shown) with multisystemic clinical manifestations, without deafness, carrying the m.1555A>G (homoplasmic). It is possible that there is a genetic heterogeneity for this mutation, similar to that observed for the m.3243A>G. In fact, as described by Petruzzella et al (1994) , differences in localized concentration and spatial distribution of mutant mtDNA in individual cells and tissues may lead to distinct clinical phenotypes.
The main limitation of this study is the small number of cases. However, the results are coincident with the available literature, besides the limited number of studies. Another restraint is the fact that data was retrospectively reviewed from patient's files and some antenatal information could be lost.
The children observed were in the first decade of life and so the mutations found were probably more frequent with earlier manifestations. Von Kleist-Retzow et al (2003) concluded that the time course and/or tissue specificity of disease expression rather than the type or severity of the enzyme deficiency should predict the antenatal expression pattern of the disease.
Our purpose to identify a possible association between MRC disorders and a more specific and earlier manifestation and/or diagnostic clinical sign was not fully accomplished. Intrauterine growth restriction is the main antenatal manifestation in MRCD. However, the possible causes of IUGR are innumerous. Its main cause is related with placental insufficiency, but it may also be due to a large number of other conditions, such as congenital anomalies, infections and multifactorial anomalies (Graça 2010) . The incidence of MRCD in children with IUGR has not been described yet, but we assume that is residual. For the reasons exposed, we think that a future multicentric study to assess the real importance of MRCD in IUGR is of great importance.
None of the antenatal manifestations found in the present study were typical and/or can be found in all cases of MRCD in order to increase clinical suspicious of this pathology when found in fetal life. This fact limits our capacity to identify, diagnose and act in antenatal period.
On the other hand, genetic counseling requires exact knowledge of the mode of inheritance. Most disorders occur sporadically, although some are inherited in an autosomal recessive or dominant and maternal inheritance . Besides the incomplete knowledge of the tissue distribution of MRCD, its change during development and its quantitative relationship to disease severity, compromises the possibility of prenatal diagnosis.
In conclusion, although a huge number of MRCD do not have antenatal expression, some cases with early neonatal/ infant expression can present some manifestations in fetal life. We are aware that IUGR is not specific, and probably associated to other diseases, but its presence and other isolated anomalies should alert clinicians to the possibility of MRCD.
To our knowledge, the present study is the first report of such a large series with identified molecular defect of antenatal manifestations cases. Although more studies are needed, the present work is a significant contribution to the study of mitochondrial physiology and activity in embryological development, allowing the assessment of the mitochondrial disease development in fetal life. This knowledge will probably contribute to improve our ability to suspect and/or diagnose a mitochondrial respiratory chain disorder from an antenatal manifestation.
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